chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date; No adverse event; Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date; This spontaneous case was reported by an other health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date), PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date) and NO ADVERSE EVENT (No adverse event) in a 74-year-old patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 058A22-2A) for COVID-19 prophylaxis.     No Medical History information was reported.    On 07-Jul-2022, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 07-Jul-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date) and NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date), PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for EXPIRED PRODUCT ADMINISTERED (Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date) and PRODUCT STORAGE ERROR (Vaccine was stored in refrigerator on 04-Jun-2022 and administered the vaccine to the patient after the 30 days by used date).    No concomitant medications were reported.  The patient received half dose of Moderna vaccine.  The vial had not undergone any temperature excursions.  The vial was initially stored in the refrigerator on 04-Jun-2022 and 35 vials were affected.  No treatment medications were reported.
Information has been received from a physician concerning a 68 year old female who on 04-OCT-2007 was vaccinated with Zostavax (lot# 658208/0886U). It was reported that on 12-OCT-2007, she developed chicken pox and was hospitalized. Current patient status was not reported. A product quality complaint was not reported. Additional information has been requested.
I received shot at 3pm.  I started feeling joint paint around 7pm, I was managing with ibuprofen thru the night. By 6am I developed fever, nausea, and burning under my skin all over my body. I was dizzy and started vomiting, and couldn't even hold down a sip of water. My husband took me to urgent care around 1pm, and they referred me to the ER. I didn't get a bed and IV fluids til after 5pm, my condition worsened and my fever reached 103. They gave me morphine IM for pain, Zofram for nausea and vomiting, and IV fluids. Tylenol for fever. They released me after 11pm, once I was able to drink water and hold it down.
No additional AE reported; Office manager reports ROTATEQ was administered after a temperature excursion to 23 patients.; This spontaneous report has been received from an office manager referring to a patient of unknown age and gender. The patient's concurrent conditions, medical history, concomitant medications, previous drug reactions, or allergies were not provided.    On 01-JUL-2022, the patient was vaccinated with an improperly stored dose of rotavirus vaccine, live, oral, pentavalent (ROTATEQ) once, (lot number W011279 has been verified to be a valid lot number, expiry date 02-NOV-2023) as prophylaxis (strength, dose, route of administration, and anatomical location, date were not provided) (product storage error).  The rotavirus vaccine, live, oral, pentavalent (ROTATEQ) was stored at a temperature of 9 degree Celcius (C) for the time frame of 1 hour and 32 minutes. There was no previous temperature excursion.  No additional adverse events reported.  This is one of several reports received from the same reporter.
Constipation; Sharp pain; Fever; This spontaneous case was reported by a consumer and describes the occurrence of CONSTIPATION (constipation), PAIN (sharp pain) and PYREXIA (fever) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. unknown) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced CONSTIPATION (constipation), PAIN (sharp pain) and PYREXIA (fever). The patient was treated with PARACETAMOL (TYLENOL) for Adverse event, at a dose of 1 dosage form. At the time of the report, CONSTIPATION (constipation) and PAIN (sharp pain) outcome was unknown and PYREXIA (fever) had resolved.            No concomitant medication were reported.
Smallpox shot was uneventful.  After scab fell off while overseas wound started to heal up.  Wound did not heal like everyone else.  Scar did not harden up but stayed sensitive and ichy with a red transparent soft protective covering.
shingles; Information has been received from a lawyer regarding a case in litigation concerning a male patient of unknown age. No information was provided regarding medical history, concurrent conditions, or concomitant medications.   On or about 03-MAR-2010, the patient was vaccinated with zoster vaccine live (ZOSTAVAX) (lot#, expiration date, dose, dose# and route not specified) for the long-term prevention of shingles and zoster-related conditions.   On an unspecified date, the patient experienced shingles which lead to hospitalization. On an unspecified date, the patient was treated by a healthcare provider for shingles. As a direct and proximate result of the patient's use of the zoster vaccine live (ZOSTAVAX) vaccine, the patient had and would continue suffer ongoing injuries, including but not limited to: mental and physical pain and suffering; medical care and treatment for these injuries; significant medical and related expenses as a result of these injuries, including but not limited to medical losses and costs include care for hospitalization, physician care, monitoring, treatment, medications, and supplies; diminished capacity for the enjoyment of life; diminished quality of life; increased risk of premature death, aggravation of preexisting conditions and activation of latent conditions; and other losses and damages; and will continue to suffer such losses, and damages in the future.   The outcome of the event shingles was not reported. The reporter considered the event to be related to zoster vaccine live (ZOSTAVAX).   Additional information has been requested.
NUMB LIPS AND TONGUE, WELT ON ARM SIZE OF BASEBALL, TRAVELING UP NECK TO TOP OF HEAD, METALLIC TASTE
Information regarding Prevnar vaccine was received from a healthcare professional regarding a patient who was administered Prevnar intradermally instead of the Tine Test; the injection site was very red and warm. The patient received a dose in 2006. On an unknown date in 2006, the patient was administered Prevnar instead of a Tine Test. The vaccine was given intradermally. The injection site was very red and warm. The outcome is unknown. No additional information was available at the time of this report.
7/19/21 EHR visit  note Immunization Reaction      pt here with mom for a reaction to imms from friday. friday evening fevers til saturday now redness warm to touch and swelling. it has improved.   patient did not die unable to uncheck the  box Mother noted redness on the left anterior thigh where Patient had 2 vaccines on Friday evening 7/16/21. He spiked a 101 degree on Friday night to Saturday. The fever has resolved.  The redness is still present. Hurts when it is touched. No other symptoms. He is walking well. Patient had fever and he had redness around the vaccine shot on the left anterior thigh. Discussed that this is due to a local reaction to vaccine-most likely due to the Pentacel . He had Pentacel and Hep A on the left thigh and Varivax on the right thigh. Give Benadryl 12.5 mg q 6-8 hrs until the redness is gone.Recheck  if with worsening symptoms.  Tylenol 1 tsp q 4 hours as needed for fever or pain. Has not returned to clinic appointment 7/20/21 canceled
right tear trough is sore to touch; hard and swollen enough that my eyelashes intertwine; This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 08-Jul-2021 and was forwarded to Moderna on 08-Jul-2021.    This spontaneous case was reported by an other health care professional and describes the occurrence of EYE PAIN (right tear trough is sore to touch) and EYE SWELLING (hard and swollen enough that my eyelashes intertwine) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Previously administered products included for an unreported indication: RESTYLANE (Patient received Restylane injection to her tear trough area.) in July 2020 and RESTYLANE since 2021.   In January 2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. In February 2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In March 2021, the patient experienced EYE PAIN (right tear trough is sore to touch) and EYE SWELLING (hard and swollen enough that my eyelashes intertwine). At the time of the report, EYE PAIN (right tear trough is sore to touch) and EYE SWELLING (hard and swollen enough that my eyelashes intertwine) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Concomitant medications details are not provided by the Reporter. In JULY2021 Patient had Restylane injection to her tear trough area and had both Moderna vaccines in Jan2021 and Feb2021. Since Mar2021,Patient had  the right tear trough sore to touch, hard and swollen enough that eyelashes intertwined. Patient had the fillers performed. She received Restylane injection to her tear trough area July 2020.Action taken with mRNA is not applicable.   This case was linked to MOD-2021-252455 (Patient Link).
Shots given Wednesday Dec 19, 12. Developed a fever 101.8 by 9 PM. She was given TYLENOL and 45 minutes later the fever was up to 102 rectally. Mother call on cal land was instructed to give MOTRIN which she did and baby promptly vomited the MOTRIN up. She was fine by Friday Dec 21, 12.
posterior synechia in right eye, iris stuck to lens behind the iris, treatment: Prednisone eye drops &Atropine Sulfate drops, Outcome: not yet resolved, still stuck, blurry vision in right eye
approx 1 hr p/vax pt started w/swelling in the hands & hives up arms, neck, & head; pt then felt the sensation of hives in feet & all over; then have hives on chest; pt called ER-advised to take DPh;
This spontaneous report as received from a registered nurse refers to a patient of unknown age and unknown gender. Patient's concurrent conditions and relevant medical history was not reported. On 04-FEB-2015, the patient was vaccinated with M-M-R II (lot number: K002816 with unspecified expiration date) (dose, frequency and route unspecified) that had underwent temperature excursion (incorrect product storage). Concomitant medications were not reported. No adverse effects (no adverse event) were reported. The outcome of the events was unknown. The causality of the events with M-M-R II was not reported. Product quality issue was not involved. This is one of several reports from the same reporter. Additional information has been requested.
Caller states that she received her first dose of PFIZER at COVID facility this am. She sat for the recommended 15 minutes and started to feel dizzy, they gave her water and she left. Once she arrived home she stated that she was still feeling dizzy and that her cheek has become numb and red and it feels like it is going toward her throat. Advised caller to see immediate medical care at an urgent care or ED to r/o a severe reaction, and that if her breathing became difficult or throat felt like it was closing to call 911. Caller verbalized understanding and is seeking immediate care.
This case was reported by a physician and described the occurrence of anaphylaxis in a 53-year-old female subject who was vaccinated with FLUARIX (GlaxoSmithKline). Concurrent medical conditions included asthma, congestive heart failure, epilepsy, ill-defined condition and lupus. Historic vaccination included INFLUENZA;GlaxoSmithKline;unknown;unknown given in 2006. In 2007 the subject received a dose of FLUARIX (.5 ml, unknown route/site). In 2007, 30 minutes after vaccination with FLUARIX, the subject experienced anaphylaxis, diffuse itching and chest tightness. The subject was hospitalised and the physician considered the events were life threatening and clinically significant (or requiring intervention). The subject was administered the FLUARIX in 2006 and 2007. According to the physician, the subject reacted to FLUARIX in 2007 with anaphylaxis, diffuse itching and chest tightness. The reporting physician was a new provider for the subject. The "reaction in 2007 happened at a different facility". The reporting physician asked about the "ingredients in FLUARIX that may have caused the reaction". At the time of reporting the outcome of the events was unspecified. The physician considered the events were possibly related to vaccination with FLUARIX.
Arms & legs were red, covered in bumps, extreme itch. Flu shot approximately 10:40AM; pt reported sx at approximately 4PM. Advised pt to get an antihistamine.
Tinnitus for the last 16 hours, unusual heart palpitations, strange sensations of pain and hot/cold sensations throughout my body.
No adverse event; Patient received expired dose of a vial for 6 to 11 years "booster doses"; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received expired dose of a vial for 6 to 11 years "booster doses") and NO ADVERSE EVENT (No adverse event) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. AR4504B) for COVID-19 prophylaxis.     No Medical History information was reported.    On 14-Nov-2022, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 14-Nov-2022, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received expired dose of a vial for 6 to 11 years "booster doses"). On an unknown date, the patient experienced NO ADVERSE EVENT (No adverse event). At the time of the report, EXPIRED PRODUCT ADMINISTERED (Patient received expired dose of a vial for 6 to 11 years "booster doses") and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessment was provided for EXPIRED PRODUCT ADMINISTERED (Patient received expired dose of a vial for 6 to 11 years "booster doses").    No concomitant medications were reported.  No treatment medications were reported.
Patient received J&J vaccine on April 9th.  She stated to experience a left sided headache on 4/14/21.  She was hospitalized late on 4/17/21 and was diagnosed with a pulmonary embolism on 4/18/21.
Received vaccine in leg; Injection site bled a little when receiving the injection; A spontaneous report was received from a patient who received Moderna's COVID-19 vaccine (mRNA-1273) and experienced it bled a little when receiving the injection and vaccine was given on the leg.  The patient's medical history included history of breast cancer. No concomitant medications were reported.  On an unknown date, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (Lot number: unknown) injection unknown route for prophylaxis of COVID-19 infection. While receiving the vaccine, the patient experienced it bled a little when receiving the injection and vaccine was given on the leg. The reporter stated that the vaccine was administered on her leg as she could not receive it on her arm due to her history with breast cancer. No treatment information was provided.  Action taken with mRNA-1273 in response to the events was not provided.  The events, it bled a little when receiving the injection and vaccine was given on the leg, was considered resolved.; Reporter's Comments: This report refers to a case of product administered at inappropriate site (vaccine was given on the leg (unknown route)) for mRNA-1273 and concerns a female patient (unknown age) with history of breast cancer, who experienced the event of injection site hemorrhage. The event occurred at an unknown time after the first and only dose of mRNA-1273 vaccine administration. Based on the current limited available information and temporal association between the use of the product and the start of the event, a causal relationship cannot be excluded and the event of injection site hemorrhage is assessed as possibly related.  In addition, the patient did not provide contact information for follow up.
Patient spiked a fever 8 days after her injections. She has had the Hib vaccine before but did not react to it. She had a fever on and off the week of 8/13/18 it would break with TYLENOL. Temperature would range from 101.5-104 this lasted 5 days. A week later she spiked a higher fever 103-104.4 on and off for 3 days.
Rash at injection site 3" across lasting for several days and a blister at injection site appeared 5 days after injection 1/4" in size.
DVT in my lower right leg. I was placed on blood thinners and released from the hospital.
Full body aches, chills, fatigue, heart racing, nausea/vomiting developing morning after vaccination.
Range of motion on the left arm; couldn't lift the arm up, cannot get it in the back pocket for about 2 weeks.; Soreness on the left arm; This spontaneous case was reported by a consumer and describes the occurrence of JOINT RANGE OF MOTION DECREASED (Range of motion on the left arm), LIMB DISCOMFORT (couldn't lift the arm up, cannot get it in the back pocket for about 2 weeks.) and MYALGIA (Soreness on the left arm) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 001C21A) for COVID-19 vaccination.     No Medical History information was reported.   On 04-May-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 04-May-2021, the patient experienced JOINT RANGE OF MOTION DECREASED (Range of motion on the left arm), LIMB DISCOMFORT (couldn't lift the arm up, cannot get it in the back pocket for about 2 weeks.) and MYALGIA (Soreness on the left arm). At the time of the report, JOINT RANGE OF MOTION DECREASED (Range of motion on the left arm), LIMB DISCOMFORT (couldn't lift the arm up, cannot get it in the back pocket for about 2 weeks.) and MYALGIA (Soreness on the left arm) outcome was unknown.            No concomitant medication were reported. No treatment details were reported.
vaccine exposure during pregnancy; This spontaneous prospective pregnancy case was reported by a consumer and describes the occurrence of EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) in a 32-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 044A21A and 040B21A) for COVID-19 vaccination.     Past medical history not provided.  Concomitant products included PSYLLIUM HYDROPHILIC MUCILLOID (METAMUCIL [PSYLLIUM HYDROPHILIC MUCILLOID]) for Constipation, UBIDECARENONE (CO Q10) for Fertilization, MINERALS NOS, VITAMINS NOS (PRENATAL VITAMINS [MINERALS NOS;VITAMINS NOS]) and ESTRADIOL for Pregnancy, CALCIUM CARBONATE, COLECALCIFEROL (VITAMIN D 2000) for Vitamin D low.   On 12-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. The patient's last menstrual period was on 10-Feb-2021 and the estimated date of delivery was 14-Nov-2021. On 12-Mar-2021, the patient experienced EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy). The patient received mRNA-1273 (Moderna COVID-19 Vaccine) beginning around the  fourth week of the pregnancy.  On 12-Mar-2021, EXPOSURE DURING PREGNANCY (vaccine exposure during pregnancy) had resolved. Not Provided    DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 07-Mar-2021, Pregnancy test: Positive. On 17-Mar-2021, Blood test: (Inconclusive) Appropriate. On 17-Mar-2021, Ultrasound scan: (Inconclusive) healthy egg sack in appropriate position. On 01-Apr-2021, Blood test: (Inconclusive) Appropriate. On 01-Apr-2021, Ultrasound scan: (Inconclusive) healthy foetus, heartbeat. On 20-Apr-2021, Blood test: Appropriate. On 20-Apr-2021, Ultrasound scan: healthy fetus, heartbeat.         Patient has prior history of alcohol use. Treatment information was not provided. Action taken with mRNA-1273 in response to the event was not applicable   Most recent FOLLOW-UP information incorporated above includes: On 05-May-2021: Medication history added, Second dose information added, laboratory details added
Comparable to COVID symptoms I had in October. Fever, headache, aches,  painful"bee sting" type at injection site.
Staff member presents with severe swelling and redness to right arm. Site also very hot to touch.
Suffered from the following; 1) Moderate pain at the site of injection  2) Fever which increased to 102F 3) General body weakness Took Tylenol twice
I woke up to use the bathroom and began to break out in sweats and became very dizzy and almost in a "hazed" state.  Then I threw up a few times and I started to feel better.  I have never had a reaction to the flu shot before.
Patient has felt weak and lethargic and had no appetite what so ever for over a week now, when she eats she feels sick. She want to sleep all the time.
Chills, tiredness, headache,muscle pain, nausea, cough, dry burning eyes, flushed face and chest.
pt recvd vax;w/in 3 hrs of vax devel swelling & moderate heat at inject site;w/in 10-12 hrs of vax devel tracking & pain at inject site & lt axillary lymphadenopathy;by 13may94 devel 8cm area of discoloration at inject site;